Impact of antibiotic treatment for pulmonary exacerbations on bacterial diversity in cystic fibrosis
A diverse array of bacterial species is present in the CF airways, in addition to those recognised as clinically important. Here, we investigated the relative impact of antibiotics, used predominantly to target Pseudomonas aeruginosa during acute exacerbations, on other non-pseudomonal species. The...
Saved in:
| Published in | Journal of cystic fibrosis Vol. 12; no. 1; pp. 22 - 28 |
|---|---|
| Main Authors | , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Netherlands
Elsevier B.V
01.01.2013
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 1569-1993 1873-5010 1873-5010 |
| DOI | 10.1016/j.jcf.2012.05.008 |
Cover
Loading…
| Abstract | A diverse array of bacterial species is present in the CF airways, in addition to those recognised as clinically important. Here, we investigated the relative impact of antibiotics, used predominantly to target Pseudomonas aeruginosa during acute exacerbations, on other non-pseudomonal species.
The relative abundance of viable P. aeruginosa and non-pseudomonal species was determined in sputa from 12 adult CF subjects 21, 14, and 7days prior to antibiotics, day 3 of treatment, the final day of treatment, and 10–14days afterwards, by T-RFLP profiling.
Overall, relative P. aeruginosa abundance increased during antibiotic therapy compared to other bacterial species; mean abundance pre-antibiotic 51.0±36.0% increasing to 71.3±30.4% during antibiotic (ANOVA: F1,54=5.16; P<0.027). Further, the number of non-pseudomonal species detected fell; pre-antibiotic 6.0±3.3 decreasing to 3.7±3.3 during treatment (ANOVA: F1,66=5.11; P<0.027).
Antibiotic treatment directed at P. aeruginosa has an additional significant impact on non-pseudomonal, co-colonising species. |
|---|---|
| AbstractList | Abstract Background A diverse array of bacterial species is present in the CF airways, in addition to those recognised as clinically important. Here, we investigated the relative impact of antibiotics, used predominantly to target Pseudomonas aeruginosa during acute exacerbations, on other non-pseudomonal species. Methods The relative abundance of viable P. aeruginosa and non-pseudomonal species was determined in sputa from 12 adult CF subjects 21, 14, and 7 days prior to antibiotics, day 3 of treatment, the final day of treatment, and 10–14 days afterwards, by T-RFLP profiling. Results Overall, relative P. aeruginosa abundance increased during antibiotic therapy compared to other bacterial species; mean abundance pre-antibiotic 51.0 ± 36.0% increasing to 71.3 ± 30.4% during antibiotic (ANOVA: F1,54 = 5.16; P < 0.027). Further, the number of non-pseudomonal species detected fell; pre-antibiotic 6.0 ± 3.3 decreasing to 3.7 ± 3.3 during treatment (ANOVA: F1,66 = 5.11; P < 0.027). Conclusions Antibiotic treatment directed at P. aeruginosa has an additional significant impact on non-pseudomonal, co-colonising species. A diverse array of bacterial species is present in the CF airways, in addition to those recognised as clinically important. Here, we investigated the relative impact of antibiotics, used predominantly to target Pseudomonas aeruginosa during acute exacerbations, on other non-pseudomonal species. The relative abundance of viable P. aeruginosa and non-pseudomonal species was determined in sputa from 12 adult CF subjects 21, 14, and 7days prior to antibiotics, day 3 of treatment, the final day of treatment, and 10–14days afterwards, by T-RFLP profiling. Overall, relative P. aeruginosa abundance increased during antibiotic therapy compared to other bacterial species; mean abundance pre-antibiotic 51.0±36.0% increasing to 71.3±30.4% during antibiotic (ANOVA: F1,54=5.16; P<0.027). Further, the number of non-pseudomonal species detected fell; pre-antibiotic 6.0±3.3 decreasing to 3.7±3.3 during treatment (ANOVA: F1,66=5.11; P<0.027). Antibiotic treatment directed at P. aeruginosa has an additional significant impact on non-pseudomonal, co-colonising species. A diverse array of bacterial species is present in the CF airways, in addition to those recognised as clinically important. Here, we investigated the relative impact of antibiotics, used predominantly to target Pseudomonas aeruginosa during acute exacerbations, on other non-pseudomonal species. The relative abundance of viable P. aeruginosa and non-pseudomonal species was determined in sputa from 12 adult CF subjects 21, 14, and 7 days prior to antibiotics, day 3 of treatment, the final day of treatment, and 10-14 days afterwards, by T-RFLP profiling. Overall, relative P. aeruginosa abundance increased during antibiotic therapy compared to other bacterial species; mean abundance pre-antibiotic 51.0±36.0% increasing to 71.3±30.4% during antibiotic (ANOVA: F(1,54)=5.16; P<0.027). Further, the number of non-pseudomonal species detected fell; pre-antibiotic 6.0±3.3 decreasing to 3.7±3.3 during treatment (ANOVA: F(1,66)=5.11; P<0.027). Antibiotic treatment directed at P. aeruginosa has an additional significant impact on non-pseudomonal, co-colonising species. A diverse array of bacterial species is present in the CF airways, in addition to those recognised as clinically important. Here, we investigated the relative impact of antibiotics, used predominantly to target Pseudomonas aeruginosa during acute exacerbations, on other non-pseudomonal species.BACKGROUNDA diverse array of bacterial species is present in the CF airways, in addition to those recognised as clinically important. Here, we investigated the relative impact of antibiotics, used predominantly to target Pseudomonas aeruginosa during acute exacerbations, on other non-pseudomonal species.The relative abundance of viable P. aeruginosa and non-pseudomonal species was determined in sputa from 12 adult CF subjects 21, 14, and 7 days prior to antibiotics, day 3 of treatment, the final day of treatment, and 10-14 days afterwards, by T-RFLP profiling.METHODSThe relative abundance of viable P. aeruginosa and non-pseudomonal species was determined in sputa from 12 adult CF subjects 21, 14, and 7 days prior to antibiotics, day 3 of treatment, the final day of treatment, and 10-14 days afterwards, by T-RFLP profiling.Overall, relative P. aeruginosa abundance increased during antibiotic therapy compared to other bacterial species; mean abundance pre-antibiotic 51.0±36.0% increasing to 71.3±30.4% during antibiotic (ANOVA: F(1,54)=5.16; P<0.027). Further, the number of non-pseudomonal species detected fell; pre-antibiotic 6.0±3.3 decreasing to 3.7±3.3 during treatment (ANOVA: F(1,66)=5.11; P<0.027).RESULTSOverall, relative P. aeruginosa abundance increased during antibiotic therapy compared to other bacterial species; mean abundance pre-antibiotic 51.0±36.0% increasing to 71.3±30.4% during antibiotic (ANOVA: F(1,54)=5.16; P<0.027). Further, the number of non-pseudomonal species detected fell; pre-antibiotic 6.0±3.3 decreasing to 3.7±3.3 during treatment (ANOVA: F(1,66)=5.11; P<0.027).Antibiotic treatment directed at P. aeruginosa has an additional significant impact on non-pseudomonal, co-colonising species.CONCLUSIONSAntibiotic treatment directed at P. aeruginosa has an additional significant impact on non-pseudomonal, co-colonising species. |
| Author | van der Gast, C.J. Connett, G.J. Stressmann, F.A. Daniels, T.W.V. Jones, G.R. Carroll, M.P. Rogers, G.B. Bruce, K.D. Legg, J.P. |
| Author_xml | – sequence: 1 givenname: T.W.V. surname: Daniels fullname: Daniels, T.W.V. organization: Cystic Fibrosis Unit, Southampton University Hospitals NHS Trust, Southampton, SO16 6YD, UK – sequence: 2 givenname: G.B. surname: Rogers fullname: Rogers, G.B. email: geraint.rogers@kcl.ac.uk organization: Molecular Microbiology Research Laboratory, Institute of Pharmaceutical Science, King's College London, London, SE1 9NH, UK – sequence: 3 givenname: F.A. surname: Stressmann fullname: Stressmann, F.A. organization: Institut Pasteur, Unité de Génétique des Biofilms, 25‐28 Rue du Docteur Roux, 75724 Paris Cedex 15, France – sequence: 4 givenname: C.J. surname: van der Gast fullname: van der Gast, C.J. organization: NERC Centre for Ecology and Hydrology, Wallingford, OX10 8BB, UK – sequence: 5 givenname: K.D. surname: Bruce fullname: Bruce, K.D. organization: Molecular Microbiology Research Laboratory, Institute of Pharmaceutical Science, King's College London, London, SE1 9NH, UK – sequence: 6 givenname: G.R. surname: Jones fullname: Jones, G.R. organization: Health Protection Agency, Southampton General Hospital, Southampton, SO16 6YD, UK – sequence: 7 givenname: G.J. surname: Connett fullname: Connett, G.J. organization: Cystic Fibrosis Unit, Southampton University Hospitals NHS Trust, Southampton, SO16 6YD, UK – sequence: 8 givenname: J.P. surname: Legg fullname: Legg, J.P. organization: Cystic Fibrosis Unit, Southampton University Hospitals NHS Trust, Southampton, SO16 6YD, UK – sequence: 9 givenname: M.P. surname: Carroll fullname: Carroll, M.P. organization: Cystic Fibrosis Unit, Southampton University Hospitals NHS Trust, Southampton, SO16 6YD, UK |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/22717533$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkk-L1TAUxYuMOH_0A7iRLN203qRNmyIIMqgzMOBCBXchSW8gtU2eSd7g-_amvpnNwIyLkCzO7-Tee-55deKDx6p6TaGhQPt3czMb2zCgrAHeAIhn1RkVQ1tzoHBS3rwfazqO7Wl1ntIMQAcYxIvqlLGBDrxtz6rpet0pk0mwRPnstAvZGZIjqryiz8SGSHb7ZQ1exQPBP8pg1Cq74BMJnujCYnRqIZO7xZhcPhDniTmkzcY6HUNy6WX13Kol4au7-6L68fnT98ur-ubrl-vLjze1KQXn2ooBhRBcUNpZ6AAY7_tOKKSdFmBawTifBkst56YcxYU22uqubzkXqMf2onp79N3F8HuPKcvVJYPLojyGfZKUtQMHxjpepG_upHu94iR30a2lQ3k_mSIYjgJTWkgRrTQu_2s8R-UWSUFuGchZlgzkloEELksGhaQPyHvzp5j3RwbLeG4dRpmMQ29wchFNllNwT9IfHtBmcd4ZtfzCA6Y57KMvc5dUpsLIb9tebGtBGQCM3c9iMD5u8J_P_wLaosck |
| CitedBy_id | crossref_primary_10_1038_s41598_020_59048_6 crossref_primary_10_1371_journal_pone_0062917 crossref_primary_10_1097_CPM_0000000000000108 crossref_primary_10_1089_mdr_2014_0024 crossref_primary_10_1183_09031936_00203013 crossref_primary_10_1007_s10482_016_0707_4 crossref_primary_10_1586_ers_13_24 crossref_primary_10_1016_S0140_6736_14_61137_5 crossref_primary_10_1186_2049_2618_1_27 crossref_primary_10_1016_j_jcf_2021_10_001 crossref_primary_10_1016_S2213_2600_14_70213_9 crossref_primary_10_1016_j_clim_2015_05_022 crossref_primary_10_1097_MCP_0000000000000419 crossref_primary_10_1186_s12866_021_02159_5 crossref_primary_10_1016_S1773_035X_15_72820_0 crossref_primary_10_1513_AnnalsATS_201306_159MG crossref_primary_10_1038_srep10241 crossref_primary_10_1513_AnnalsATS_201609_668OC crossref_primary_10_1016_j_micpath_2018_09_010 crossref_primary_10_3389_fcimb_2016_00041 crossref_primary_10_1007_s12223_017_0562_3 crossref_primary_10_1128_aac_02246_21 crossref_primary_10_1371_journal_ppat_1005258 crossref_primary_10_1016_S2213_2600_15_00476_2 crossref_primary_10_1586_17476348_2014_966693 crossref_primary_10_3390_pathogens4010066 crossref_primary_10_1038_s41579_020_00477_5 crossref_primary_10_1016_j_tim_2013_03_004 crossref_primary_10_1111_resp_13411 crossref_primary_10_1007_s11046_017_0185_x crossref_primary_10_1128_JCM_02555_14 crossref_primary_10_1016_j_jaci_2017_03_044 crossref_primary_10_1038_ismej_2015_198 crossref_primary_10_1007_s11515_013_1267_x crossref_primary_10_1128_JCM_02164_13 crossref_primary_10_1371_journal_pone_0142097 crossref_primary_10_1016_j_jcf_2013_01_007 crossref_primary_10_1016_j_clinmicnews_2016_10_004 crossref_primary_10_1016_j_jcf_2020_12_012 crossref_primary_10_1016_j_jcf_2023_11_010 crossref_primary_10_1038_srep23745 crossref_primary_10_1186_s40168_015_0074_9 crossref_primary_10_1042_ETLS20170043 crossref_primary_10_1186_s40168_017_0289_z crossref_primary_10_3390_antibiotics10070827 crossref_primary_10_1016_j_bioflm_2020_100031 crossref_primary_10_1513_AnnalsATS_201211_107OC crossref_primary_10_1016_j_jcf_2015_03_012 |
| Cites_doi | 10.1111/j.1469-0691.2010.03189.x 10.1016/S0924-8579(00)00333-2 10.1136/thx.2010.157875 10.1128/AAC.48.4.1168-1174.2004 10.1164/ajrccm/141.4_Pt_1.914 10.1136/thx.2010.137281 10.1371/journal.ppat.1000184 10.1128/JB.01651-09 10.1128/CMR.15.2.194-222.2002 10.1038/ismej.2010.175 10.1111/j.1365-2958.2006.05390.x 10.1046/j.1365-2958.2003.03803.x 10.1128/JCM.42.11.5176-5183.2004 10.1016/j.mimet.2006.04.015 10.1038/nature03912 10.1016/j.jcf.2011.06.014 10.1126/science.288.5469.1251 10.1034/j.1399-3003.2000.16d30.x 10.1016/j.micinf.2003.08.009 10.1056/NEJM199409083311003 10.1016/j.diagmicrobio.2008.06.011 10.1073/pnas.0804326105 10.1073/pnas.1120577109 10.1136/thoraxjnl-2011-200932 10.1007/s10096-009-0749-x 10.1371/journal.pone.0002908 10.1128/JCM.01650-10 10.1016/S0022-3476(99)70197-6 |
| ContentType | Journal Article |
| Copyright | 2012 European Cystic Fibrosis Society. European Cystic Fibrosis Society. Copyright © 2012 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved. |
| Copyright_xml | – notice: 2012 European Cystic Fibrosis Society. – notice: European Cystic Fibrosis Society. – notice: Copyright © 2012 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved. |
| DBID | 6I. AAFTH AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1016/j.jcf.2012.05.008 |
| DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1873-5010 |
| EndPage | 28 |
| ExternalDocumentID | 22717533 10_1016_j_jcf_2012_05_008 S156919931200094X 1_s2_0_S156919931200094X |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GroupedDBID | --- --K --M .1- .FO .~1 0R~ 1B1 1P~ 1~. 1~5 29K 4.4 457 4G. 53G 5GY 5VS 7-5 71M 8P~ AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AATTM AAXKI AAXUO AAYWO ABBQC ABFNM ABJNI ABMAC ABMZM ABWVN ABXDB ACDAQ ACGFS ACIEU ACRLP ACRPL ACVFH ADBBV ADCNI ADEZE ADMUD ADNMO ADVLN AEBSH AEIPS AEKER AENEX AEUPX AEVXI AEXQZ AFJKZ AFPUW AFRHN AFTJW AFXIZ AGCQF AGHFR AGUBO AGYEJ AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP AXJTR BKOJK BLXMC BNPGV CS3 D-I DU5 EBS EFJIC EFKBS EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FIRID FNPLU FYGXN G-Q GBLVA HVGLF HZ~ IHE IXB J1W KOM M41 MO0 N9A O-L O9- OAUVE OI- OK1 OU. OZT P-8 P-9 P2P PC. Q38 ROL RPZ SDF SDG SEL SES SEW SPCBC SSH SSZ T5K UHS Z5R ~G- 0SF 6I. AACTN AAFTH ABVKL AFCTW AFKWA AJOXV AMFUW NCXOZ RIG AAIAV ABLVK ABYKQ AJBFU EFLBG LCYCR AAYXX AGRNS CITATION CGR CUY CVF ECM EIF NPM 7X8 |
| ID | FETCH-LOGICAL-c501t-f87e88858114f0400256648ae14b80c38255d7f1f55cf55a58bcbfb463558eb93 |
| IEDL.DBID | IXB |
| ISSN | 1569-1993 1873-5010 |
| IngestDate | Fri Jul 11 02:32:19 EDT 2025 Thu Apr 03 07:02:25 EDT 2025 Tue Jul 01 04:22:09 EDT 2025 Thu Apr 24 22:56:52 EDT 2025 Fri Feb 23 02:35:15 EST 2024 Sun Feb 23 10:19:05 EST 2025 Tue Aug 26 16:35:03 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Antibiotics Bacterial diversity T-RFLP Pulmonary exacerbation Relative abundance |
| Language | English |
| License | http://www.elsevier.com/open-access/userlicense/1.0 https://www.elsevier.com/tdm/userlicense/1.0 https://www.elsevier.com/open-access/userlicense/1.0 Copyright © 2012 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c501t-f87e88858114f0400256648ae14b80c38255d7f1f55cf55a58bcbfb463558eb93 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | https://www.sciencedirect.com/science/article/pii/S156919931200094X |
| PMID | 22717533 |
| PQID | 1237502245 |
| PQPubID | 23479 |
| PageCount | 7 |
| ParticipantIDs | proquest_miscellaneous_1237502245 pubmed_primary_22717533 crossref_citationtrail_10_1016_j_jcf_2012_05_008 crossref_primary_10_1016_j_jcf_2012_05_008 elsevier_sciencedirect_doi_10_1016_j_jcf_2012_05_008 elsevier_clinicalkeyesjournals_1_s2_0_S156919931200094X elsevier_clinicalkey_doi_10_1016_j_jcf_2012_05_008 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2013-01-01 |
| PublicationDateYYYYMMDD | 2013-01-01 |
| PublicationDate_xml | – month: 01 year: 2013 text: 2013-01-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | Netherlands |
| PublicationPlace_xml | – name: Netherlands |
| PublicationTitle | Journal of cystic fibrosis |
| PublicationTitleAlternate | J Cyst Fibros |
| PublicationYear | 2013 |
| Publisher | Elsevier B.V |
| Publisher_xml | – name: Elsevier B.V |
| References | Stressmann, Rogers, Klem, Lilley, Donaldson, Daniels (bb0040) 2011; 49 Duan, Dammel, Stein, Rabin, Surette (bb0055) 2003 Dec; 50 Sibley, Parkins, Rabin, Duan, Norgaard, Surette (bb0020) Sep 30 2008; 105 Wood, Leech, Ohman (bb0145) Oct 2006; 62 Lyczak, Cannon, Pier (bb0005) 2002; 15 Fuchs, Borowitz, Christiansen, Morris, Nash, Ramsey (bb0085) 1994; 331 Mulcahy, Burns, Lory, Lewis (bb0135) Dec 2010; 192 Bittar, Richet, Dubus, Reynaud-Gaubert, Stremler, Sarles (bb0025) Aug 6 2008; 3 Nocker, Cheung, Camper (bb0075) Nov 2006; 67 Döring, Conway, Heijerman, Hodson, Hoiby, Smyth (bb0100) Oct 2000; 16 Bagge, Hentzer, Andersen, Ciofu, Givskov, Hoiby (bb0150) Apr 2004; 48 Oliver, Canton, Campo, Baquero, Blazquez (bb0155) May 19 2000; 288 van der Gast, Walker, Stressmann, Rogers, Scott, Daniels (bb0035) May 2011; 5 Rogers, Carroll, Serisier, Hockey, Jones, Bruce (bb0015) 2004; 42 Rogers, Hoffman, Döring (bb0125) Dec 2011; 10 Regelmann, Elliott, Warwick, Clawson (bb0110) 1990; 141 Cystic Fibrosis Trust (bb0010) 2010 Rogers, Marsh, Stressmann, Allen, Daniels, Carroll (bb0070) 2010; 16 Rogers, Marsh, Stressmann, Allen, Daniels, Carroll (bb0095) Nov 2010; 16 Ratjen (bb0105) Feb 2001; 17 Rogers, Stressmann, Koller, Daniels, Carroll, Bruce (bb0065) 2008; 62 Stressmann FA, Rogers GB, van der Gast CJ, Marsh P, Vermeer LS, Carroll MP, et al. Long-term cultivation-independent microbial diversity analysis demonstrates that bacterial communities infecting the adult cystic fibrosis lung show stability and resilience. Thorax in press Armougom, Bittar, Stremler, Rolain, Robert, Dubus (bb0030) Sep 2009; 28 Tunney, Klem, Fodor, Gilpin, Moriarty, McGrath (bb0045) 2011; 66 . Jones (bb0115) Jul 2011; 66 Hoffman, D'Argenio, MacCoss, Zhang, Jones, Miller (bb0140) Aug 25 2005; 436 Standards Unit Department for Evaluations Standards and Training Centre for Infections (bb0080) 2008 Zhao, Schloss, Kalikin, Carmody, Foster, Petrosino (bb0050) Mar 26 2012; 109 Sibley, Duan, Fischer, Parkins, Storey, Rabin (bb0060) 2008; 4 Smith, Doershuk, Goldmann, Gore, Hilman, Marks (bb0120) Apr 1999; 134 Drenkard (bb0130) Nov 2003; 5 Standards Unit Department for Evaluations Standards and Training Centre for Infections (10.1016/j.jcf.2012.05.008_bb0080) 2008 Rogers (10.1016/j.jcf.2012.05.008_bb0065) 2008; 62 Bittar (10.1016/j.jcf.2012.05.008_bb0025) 2008; 3 Duan (10.1016/j.jcf.2012.05.008_bb0055) 2003; 50 Wood (10.1016/j.jcf.2012.05.008_bb0145) 2006; 62 Bagge (10.1016/j.jcf.2012.05.008_bb0150) 2004; 48 Rogers (10.1016/j.jcf.2012.05.008_bb0125) 2011; 10 Jones (10.1016/j.jcf.2012.05.008_bb0115) 2011; 66 Smith (10.1016/j.jcf.2012.05.008_bb0120) 1999; 134 Rogers (10.1016/j.jcf.2012.05.008_bb0070) 2010; 16 Regelmann (10.1016/j.jcf.2012.05.008_bb0110) 1990; 141 Drenkard (10.1016/j.jcf.2012.05.008_bb0130) 2003; 5 Mulcahy (10.1016/j.jcf.2012.05.008_bb0135) 2010; 192 van der Gast (10.1016/j.jcf.2012.05.008_bb0035) 2011; 5 Sibley (10.1016/j.jcf.2012.05.008_bb0060) 2008; 4 Sibley (10.1016/j.jcf.2012.05.008_bb0020) 2008; 105 Nocker (10.1016/j.jcf.2012.05.008_bb0075) 2006; 67 Armougom (10.1016/j.jcf.2012.05.008_bb0030) 2009; 28 10.1016/j.jcf.2012.05.008_bb0090 Lyczak (10.1016/j.jcf.2012.05.008_bb0005) 2002; 15 Rogers (10.1016/j.jcf.2012.05.008_bb0015) 2004; 42 Tunney (10.1016/j.jcf.2012.05.008_bb0045) 2011; 66 Cystic Fibrosis Trust (10.1016/j.jcf.2012.05.008_bb0010) 2010 Ratjen (10.1016/j.jcf.2012.05.008_bb0105) 2001; 17 Oliver (10.1016/j.jcf.2012.05.008_bb0155) 2000; 288 Zhao (10.1016/j.jcf.2012.05.008_bb0050) 2012; 109 Döring (10.1016/j.jcf.2012.05.008_bb0100) 2000; 16 Hoffman (10.1016/j.jcf.2012.05.008_bb0140) 2005; 436 Fuchs (10.1016/j.jcf.2012.05.008_bb0085) 1994; 331 Stressmann (10.1016/j.jcf.2012.05.008_bb0040) 2011; 49 Rogers (10.1016/j.jcf.2012.05.008_bb0095) 2010; 16 |
| References_xml | – year: 2010 ident: bb0010 article-title: Laboratory standards for processing microbiological samples from people with cystic fibrosis - report of the UK cystic fibrosis trust microbiology standards working group – volume: 42 start-page: 5176 year: 2004 end-page: 5183 ident: bb0015 article-title: Characterization of bacterial community diversity in cystic fibrosis lung infections by use of 16s ribosomal DNA terminal restriction fragment length polymorphism profiling publication-title: J Clin Microbiol – volume: 28 start-page: 1151 year: Sep 2009 end-page: 1154 ident: bb0030 article-title: Microbial diversity in the sputum of a cystic fibrosis patient studied with 16S rDNA pyrosequencing publication-title: Eur J Clin Microbiol Infect Dis – volume: 109 start-page: 5809 year: Mar 26 2012 end-page: 5814 ident: bb0050 article-title: Decade-long bacterial community dynamics in cystic fibrosis airways publication-title: Proc Natl Acad Sci U S A – volume: 48 start-page: 1168 year: Apr 2004 end-page: 1174 ident: bb0150 article-title: Dynamics and spatial distribution of beta-lactamase expression in Pseudomonas aeruginosa biofilms publication-title: Antimicrob Agents Chemother – volume: 331 start-page: 637 year: 1994 end-page: 642 ident: bb0085 article-title: Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group publication-title: N Engl J Med – volume: 15 start-page: 194 year: 2002 end-page: 222 ident: bb0005 article-title: Lung infections associated with cystic fibrosis publication-title: Clin Microbiol Rev – volume: 436 start-page: 1171 year: Aug 25 2005 end-page: 1175 ident: bb0140 article-title: Aminoglycoside antibiotics induce bacterial biofilm formation publication-title: Nature – start-page: 57 year: 2008 ident: bb0080 article-title: Investigation of bronchoalveolar lavage, sputum and associated specimens – volume: 4 start-page: e1000184 year: 2008 ident: bb0060 article-title: Discerning the complexity of community interactions using a Drosophila model of polymicrobial infections publication-title: PLoS Pathog – volume: 192 start-page: 6191 year: Dec 2010 end-page: 6199 ident: bb0135 article-title: Emergence of Pseudomonas aeruginosa strains producing high levels of persister cells in patients with cystic fibrosis publication-title: J Bacteriol – volume: 5 start-page: 780 year: May 2011 end-page: 791 ident: bb0035 article-title: Partitioning core and satellite taxa from within cystic fibrosis lung bacterial communities publication-title: ISME J – volume: 141 start-page: 914 year: 1990 end-page: 921 ident: bb0110 article-title: Reduction of sputum Pseudomonas aeruginosa density by antibiotics improves lung function in cystic fibrosis more than do bronchodilators and chest physiotherapy alone publication-title: Am Rev Respir Dis – reference: Stressmann FA, Rogers GB, van der Gast CJ, Marsh P, Vermeer LS, Carroll MP, et al. Long-term cultivation-independent microbial diversity analysis demonstrates that bacterial communities infecting the adult cystic fibrosis lung show stability and resilience. Thorax in press, – volume: 288 start-page: 1251 year: May 19 2000 end-page: 1254 ident: bb0155 article-title: High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection publication-title: Science – volume: 5 start-page: 1213 year: Nov 2003 end-page: 1219 ident: bb0130 article-title: Antimicrobial resistance of Pseudomonas aeruginosa biofilms publication-title: Microbes Infect – volume: 62 start-page: 412 year: Oct 2006 end-page: 426 ident: bb0145 article-title: Cell wall-inhibitory antibiotics activate the alginate biosynthesis operon in Pseudomonas aeruginosa: roles of sigma (AlgT) and the AlgW and Prc proteases publication-title: Mol Microbiol – volume: 3 start-page: e2908 year: Aug 6 2008 ident: bb0025 article-title: Molecular detection of multiple emerging pathogens in sputa from cystic fibrosis patients publication-title: PLoS One – volume: 105 start-page: 15070 year: Sep 30 2008 end-page: 15075 ident: bb0020 article-title: A polymicrobial perspective of pulmonary infections exposes an enigmatic pathogen in cystic fibrosis patients publication-title: Proc Natl Acad Sci U S A – volume: 49 start-page: 281 year: 2011 end-page: 291 ident: bb0040 article-title: Analysis of the bacterial communities present in lungs of patients with cystic fibrosis from American and British centers publication-title: J Clin Microbiol – volume: 66 start-page: 579 year: 2011 end-page: 584 ident: bb0045 article-title: Use of culture and molecular analysis to determine the effect of antibiotic treatment on microbial community diversity and abundance during exacerbation in patients with cystic fibrosis publication-title: Thorax – volume: 16 start-page: 1656 year: 2010 end-page: 1658 ident: bb0070 article-title: The exclusion of dead bacterial cells is essential for accurate molecular analysis of clinical samples publication-title: Clin Microbiol Infect – volume: 67 start-page: 310 year: Nov 2006 end-page: 320 ident: bb0075 article-title: Comparison of propidium monoazide with ethidium monoazide for differentiation of live vs. dead bacteria by selective removal of DNA from dead cells publication-title: J Microbiol Methods – volume: 16 start-page: 1656 year: Nov 2010 end-page: 1658 ident: bb0095 article-title: The exclusion of dead bacterial cells is essential for accurate molecular analysis of clinical samples publication-title: Clin Microbiol Infect – volume: 62 start-page: 133 year: 2008 end-page: 141 ident: bb0065 article-title: Assessing the diagnostic importance of nonviable bacterial cells in respiratory infections publication-title: Diagn Microbiol Infect Dis – reference: . – volume: 10 start-page: 387 year: Dec 2011 end-page: 400 ident: bb0125 article-title: Novel concepts in evaluating antimicrobial therapy for bacterial lung infections in patients with cystic fibrosis publication-title: J Cyst Fibros – volume: 66 start-page: 558 year: Jul 2011 end-page: 559 ident: bb0115 article-title: Anaerobic bacteria in cystic fibrosis: pathogens or harmless commensals? publication-title: Thorax – volume: 134 start-page: 413 year: Apr 1999 end-page: 421 ident: bb0120 article-title: Comparison of a beta-lactam alone versus beta-lactam and an aminoglycoside for pulmonary exacerbation in cystic fibrosis publication-title: J Pediatr – volume: 16 start-page: 749 year: Oct 2000 end-page: 767 ident: bb0100 article-title: Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus publication-title: Eur Respir J – volume: 50 start-page: 1477 year: 2003 Dec end-page: 1491 ident: bb0055 article-title: Modulation of Pseudomonas aeruginosa gene expression by host microflora through interspecies communication publication-title: Mol Microbiol – volume: 17 start-page: 93 year: Feb 2001 end-page: 96 ident: bb0105 article-title: Changes in strategies for optimal antibacterial therapy in cystic fibrosis publication-title: Int J Antimicrob Agents – volume: 16 start-page: 1656 issue: 11 year: 2010 ident: 10.1016/j.jcf.2012.05.008_bb0070 article-title: The exclusion of dead bacterial cells is essential for accurate molecular analysis of clinical samples publication-title: Clin Microbiol Infect doi: 10.1111/j.1469-0691.2010.03189.x – start-page: 57 year: 2008 ident: 10.1016/j.jcf.2012.05.008_bb0080 article-title: Investigation of bronchoalveolar lavage, sputum and associated specimens – volume: 17 start-page: 93 issue: 2 year: 2001 ident: 10.1016/j.jcf.2012.05.008_bb0105 article-title: Changes in strategies for optimal antibacterial therapy in cystic fibrosis publication-title: Int J Antimicrob Agents doi: 10.1016/S0924-8579(00)00333-2 – volume: 66 start-page: 558 issue: 7 year: 2011 ident: 10.1016/j.jcf.2012.05.008_bb0115 article-title: Anaerobic bacteria in cystic fibrosis: pathogens or harmless commensals? publication-title: Thorax doi: 10.1136/thx.2010.157875 – volume: 48 start-page: 1168 issue: 4 year: 2004 ident: 10.1016/j.jcf.2012.05.008_bb0150 article-title: Dynamics and spatial distribution of beta-lactamase expression in Pseudomonas aeruginosa biofilms publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.48.4.1168-1174.2004 – volume: 141 start-page: 914 issue: Suppl. 4 Pt 1 year: 1990 ident: 10.1016/j.jcf.2012.05.008_bb0110 article-title: Reduction of sputum Pseudomonas aeruginosa density by antibiotics improves lung function in cystic fibrosis more than do bronchodilators and chest physiotherapy alone publication-title: Am Rev Respir Dis doi: 10.1164/ajrccm/141.4_Pt_1.914 – volume: 66 start-page: 579 issue: 7 year: 2011 ident: 10.1016/j.jcf.2012.05.008_bb0045 article-title: Use of culture and molecular analysis to determine the effect of antibiotic treatment on microbial community diversity and abundance during exacerbation in patients with cystic fibrosis publication-title: Thorax doi: 10.1136/thx.2010.137281 – volume: 4 start-page: e1000184 issue: Suppl. 10 year: 2008 ident: 10.1016/j.jcf.2012.05.008_bb0060 article-title: Discerning the complexity of community interactions using a Drosophila model of polymicrobial infections publication-title: PLoS Pathog doi: 10.1371/journal.ppat.1000184 – volume: 192 start-page: 6191 issue: 23 year: 2010 ident: 10.1016/j.jcf.2012.05.008_bb0135 article-title: Emergence of Pseudomonas aeruginosa strains producing high levels of persister cells in patients with cystic fibrosis publication-title: J Bacteriol doi: 10.1128/JB.01651-09 – volume: 15 start-page: 194 issue: Suppl. 2 year: 2002 ident: 10.1016/j.jcf.2012.05.008_bb0005 article-title: Lung infections associated with cystic fibrosis publication-title: Clin Microbiol Rev doi: 10.1128/CMR.15.2.194-222.2002 – volume: 5 start-page: 780 issue: 5 year: 2011 ident: 10.1016/j.jcf.2012.05.008_bb0035 article-title: Partitioning core and satellite taxa from within cystic fibrosis lung bacterial communities publication-title: ISME J doi: 10.1038/ismej.2010.175 – volume: 62 start-page: 412 issue: 2 year: 2006 ident: 10.1016/j.jcf.2012.05.008_bb0145 article-title: Cell wall-inhibitory antibiotics activate the alginate biosynthesis operon in Pseudomonas aeruginosa: roles of sigma (AlgT) and the AlgW and Prc proteases publication-title: Mol Microbiol doi: 10.1111/j.1365-2958.2006.05390.x – volume: 50 start-page: 1477 issue: 5 year: 2003 ident: 10.1016/j.jcf.2012.05.008_bb0055 article-title: Modulation of Pseudomonas aeruginosa gene expression by host microflora through interspecies communication publication-title: Mol Microbiol doi: 10.1046/j.1365-2958.2003.03803.x – volume: 42 start-page: 5176 issue: Suppl. 11 year: 2004 ident: 10.1016/j.jcf.2012.05.008_bb0015 article-title: Characterization of bacterial community diversity in cystic fibrosis lung infections by use of 16s ribosomal DNA terminal restriction fragment length polymorphism profiling publication-title: J Clin Microbiol doi: 10.1128/JCM.42.11.5176-5183.2004 – volume: 67 start-page: 310 issue: 2 year: 2006 ident: 10.1016/j.jcf.2012.05.008_bb0075 article-title: Comparison of propidium monoazide with ethidium monoazide for differentiation of live vs. dead bacteria by selective removal of DNA from dead cells publication-title: J Microbiol Methods doi: 10.1016/j.mimet.2006.04.015 – volume: 436 start-page: 1171 issue: 7054 year: 2005 ident: 10.1016/j.jcf.2012.05.008_bb0140 article-title: Aminoglycoside antibiotics induce bacterial biofilm formation publication-title: Nature doi: 10.1038/nature03912 – volume: 10 start-page: 387 issue: 6 year: 2011 ident: 10.1016/j.jcf.2012.05.008_bb0125 article-title: Novel concepts in evaluating antimicrobial therapy for bacterial lung infections in patients with cystic fibrosis publication-title: J Cyst Fibros doi: 10.1016/j.jcf.2011.06.014 – volume: 288 start-page: 1251 issue: 5469 year: 2000 ident: 10.1016/j.jcf.2012.05.008_bb0155 article-title: High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection publication-title: Science doi: 10.1126/science.288.5469.1251 – volume: 16 start-page: 749 issue: 4 year: 2000 ident: 10.1016/j.jcf.2012.05.008_bb0100 article-title: Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus publication-title: Eur Respir J doi: 10.1034/j.1399-3003.2000.16d30.x – volume: 16 start-page: 1656 issue: 11 year: 2010 ident: 10.1016/j.jcf.2012.05.008_bb0095 article-title: The exclusion of dead bacterial cells is essential for accurate molecular analysis of clinical samples publication-title: Clin Microbiol Infect doi: 10.1111/j.1469-0691.2010.03189.x – year: 2010 ident: 10.1016/j.jcf.2012.05.008_bb0010 – volume: 5 start-page: 1213 issue: 13 year: 2003 ident: 10.1016/j.jcf.2012.05.008_bb0130 article-title: Antimicrobial resistance of Pseudomonas aeruginosa biofilms publication-title: Microbes Infect doi: 10.1016/j.micinf.2003.08.009 – volume: 331 start-page: 637 issue: Suppl. 10 year: 1994 ident: 10.1016/j.jcf.2012.05.008_bb0085 article-title: Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group publication-title: N Engl J Med doi: 10.1056/NEJM199409083311003 – volume: 62 start-page: 133 issue: Suppl. 2 year: 2008 ident: 10.1016/j.jcf.2012.05.008_bb0065 article-title: Assessing the diagnostic importance of nonviable bacterial cells in respiratory infections publication-title: Diagn Microbiol Infect Dis doi: 10.1016/j.diagmicrobio.2008.06.011 – volume: 105 start-page: 15070 issue: 39 year: 2008 ident: 10.1016/j.jcf.2012.05.008_bb0020 article-title: A polymicrobial perspective of pulmonary infections exposes an enigmatic pathogen in cystic fibrosis patients publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.0804326105 – volume: 109 start-page: 5809 issue: 15 year: 2012 ident: 10.1016/j.jcf.2012.05.008_bb0050 article-title: Decade-long bacterial community dynamics in cystic fibrosis airways publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.1120577109 – ident: 10.1016/j.jcf.2012.05.008_bb0090 doi: 10.1136/thoraxjnl-2011-200932 – volume: 28 start-page: 1151 issue: 9 year: 2009 ident: 10.1016/j.jcf.2012.05.008_bb0030 article-title: Microbial diversity in the sputum of a cystic fibrosis patient studied with 16S rDNA pyrosequencing publication-title: Eur J Clin Microbiol Infect Dis doi: 10.1007/s10096-009-0749-x – volume: 3 start-page: e2908 issue: 8 year: 2008 ident: 10.1016/j.jcf.2012.05.008_bb0025 article-title: Molecular detection of multiple emerging pathogens in sputa from cystic fibrosis patients publication-title: PLoS One doi: 10.1371/journal.pone.0002908 – volume: 49 start-page: 281 issue: Suppl. 1 year: 2011 ident: 10.1016/j.jcf.2012.05.008_bb0040 article-title: Analysis of the bacterial communities present in lungs of patients with cystic fibrosis from American and British centers publication-title: J Clin Microbiol doi: 10.1128/JCM.01650-10 – volume: 134 start-page: 413 issue: 4 year: 1999 ident: 10.1016/j.jcf.2012.05.008_bb0120 article-title: Comparison of a beta-lactam alone versus beta-lactam and an aminoglycoside for pulmonary exacerbation in cystic fibrosis publication-title: J Pediatr doi: 10.1016/S0022-3476(99)70197-6 |
| SSID | ssj0017078 |
| Score | 2.2037807 |
| Snippet | A diverse array of bacterial species is present in the CF airways, in addition to those recognised as clinically important. Here, we investigated the relative... Abstract Background A diverse array of bacterial species is present in the CF airways, in addition to those recognised as clinically important. Here, we... |
| SourceID | proquest pubmed crossref elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 22 |
| SubjectTerms | Adolescent Adult Anti-Bacterial Agents - therapeutic use Antibiotics Azides Bacterial diversity Biodiversity Cystic Fibrosis - drug therapy Cystic Fibrosis - microbiology Disease Progression Female Humans Male Middle Aged Polymerase Chain Reaction Propidium - analogs & derivatives Pseudomonas aeruginosa - drug effects Pulmonary exacerbation Pulmonary/Respiratory Relative abundance Sputum - microbiology T-RFLP Young Adult |
| Title | Impact of antibiotic treatment for pulmonary exacerbations on bacterial diversity in cystic fibrosis |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S156919931200094X https://www.clinicalkey.es/playcontent/1-s2.0-S156919931200094X https://dx.doi.org/10.1016/j.jcf.2012.05.008 https://www.ncbi.nlm.nih.gov/pubmed/22717533 https://www.proquest.com/docview/1237502245 |
| Volume | 12 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3dS-QwEB_8APHlUO_UVW-JcE8Hdbdpsm0fdTlZT9wXT9i3kKQJVJZ22e7C-eLf7iT9ANFTuIe-lIS005nJbzozvwD8QFuOUtwYMCyRGKCYNAtUJOMgVUwahZDBatfvfDcdTR7Y7xmfbcC47YVxZZWN7699uvfWzZ1BI83BIs8H9xh5pK78LKS-Pm6GfjhiiW_im111mQTHZuM5U0epK6qI2symr_F61J7Fk3ryTnfC5Pt707-wp9-DrvfgSwMeyWX9fPuwYYoD2Llr0uNfIbvxPY-ktAQFlqu8xIGkqyUnCFDJYj1HzZPLJ2L-So1CrX_ZkbIgqmZuxhWytlqD5AXRT47LmVgMrMsqr77Bw_WvP-NJ0ByjEGg-DFeBTWKDcS5PMPSxzmYR5YxYIk3IVDLUEcaIPIttaDnXeEmeKK2sYg6KJEal0SFsFWVhjoFIJjGeljFudxkLqUVs4xnPqE6sQazTg2ErQKEbjnF31MVctMVkjwJlLpzMxZALlHkPfnZTFjXBxkeDaftVRNs5ir5OoPv_aFL83iRTNdZaiVBUOFi80agesG7mK6X8bMHzVmEEGqvLwMjClGtciKLAHGriPTiqNal7aUpjx5oanfzfoqewS_1JHe7v0BlsrZZr8x3x0kr1YfPiOezD9uXN7WTa9-bxArYTFA4 |
| linkProvider | Elsevier |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LS8QwEB58gHoR367PCJ6Estu02bZHFWVXXS8q7C0kaQIVaRe7C_rvnaQPEF_goZeSkHY6M_mmM_kG4BRtOUhwY8CwRGCAopPUk4GIvESGQkuEDEbZ886j-_7gKbwZs_EcXDZnYWxZZe37K5_uvHV9p1tLszvJsu4DRh6JLT_zqauPG8_DIqKByPZvGI4v2lSCpbNxpKn9xFZVBE1q0xV5PStH40kde6dtMfn95vQT-HSb0PUarNbokZxXD7gOczrfgKVRnR_fhHToDj2SwhCUWCazAgeStpicIEIlk9kLqp54fSf6TSiUavXPjhQ5kRV1M66QNuUaJMuJerdkzsRgZF2UWbkFT9dXj5cDr-6j4CnW86eeiSONgS6LMfYx1mgR5vTDWGg_lHFPBRgksjQyvmFM4SVYLJU0MrRYJNYyCbZhIS9yvQtEhAIDahHhfpeGPjUIbhzlGVWx0Qh2OtBrBMhVTTJue1288Kaa7JmjzLmVOe8xjjLvwFk7ZVIxbPw2mDZfhTdHR9HZcfT_v02Kvpuky9pcS-7zEgfzLyrVgbCd-Ukr_1rwpFEYjtZqUzAi18UMF6IoMAubWAd2Kk1qX5rSyNKmBnv_W_QYlgePozt-N7y_3YcV6tp22F9FB7AwfZ3pQwRPU3nkjOMDboIUoQ |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Impact+of+antibiotic+treatment+for+pulmonary+exacerbations+on+bacterial+diversity+in+cystic+fibrosis&rft.jtitle=Journal+of+cystic+fibrosis&rft.au=Daniels%2C+T.W.V&rft.au=Rogers%2C+G.B&rft.au=Stressmann%2C+F.A&rft.au=van+der+Gast%2C+C.J&rft.date=2013-01-01&rft.issn=1569-1993&rft.volume=12&rft.issue=1&rft.spage=22&rft.epage=28&rft_id=info:doi/10.1016%2Fj.jcf.2012.05.008&rft.externalDBID=ECK1-s2.0-S156919931200094X&rft.externalDocID=1_s2_0_S156919931200094X |
| thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F15691993%2FS1569199312X00080%2Fcov150h.gif |